ArticleMetabolic syndrome and related disorders2026
Albuminuria and Metabolic Dysfunction-Associated Steatotic Liver Disease with Advanced Fibrosis in Primary Care.
Article in Metabolic syndrome and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD) are linked through the cardiovascular-kidney-metabolic (CKM) health spectrum. This study examines the association between albuminuria and advanced liver fibrosis, both prognostic risk factors for severe kidney and liver outcomes, in patients with MASLD.
methodsThis was a retrospective cross-sectional study of primary care patients with MASLD between 2012 and 2023. Urinary microalbumin-to-creatinine ratio (uACR) was the primary predictor variable and categorized as elevated (≥30 mg/g) or normal (<30 mg/g). The primary outcome was a fibrosis-4 index (FIB-4) at high risk for advanced fibrosis (≥2.67). Bivariate analyses described the cohort overall and by uACR status. Logistic regression models estimated the association of an elevated uACR with a FIB-4 at high risk for advanced fibrosis.
resultsThe sample included 463 patients of whom 45% had a uACR ≥30 mg/g and 9% had an FIB-4 ≥2.67. In the unadjusted logistic Firth regression model, uACR ≥30 mg/g was associated with an increased odds of having a high-risk FIB-4 (odds ratio [OR] 2.04; 95% confidence interval [CI] 1.06-3.90). After adjusting for estimated glomerular filtration rate (eGFR), there was no significant association between uACR ≥30 mg/g and a high-risk FIB-4 (OR: 1.73; 95% CI: 0.88-3.39). Using a predictor variable combining uACR and eGFR measures, the unadjusted (OR: 3.83; 95% CI: 1.77-8.25) and adjusted (OR: 2.87; 95% CI: 1.29-6.37) logistic Firth regression models demonstrated an association between ACR ≥30 mg/g and eGFR <59 mL/min with the outcome of a high-risk FIB-4.
conclusionAlbuminuria and reduced eGFR were associated with measures of advanced fibrosis in primary care patients with MASLD, highlighting the link between CKD and MASLD along the CKM health spectrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.